Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia

Inclusion Criteria: * Male subjects or postmenopausal female subjects aged between 19-70 years * High risk patients (PROCAM risk ≥20%) on a stable statin-therapy, but at least simvastatin 20 mg/d * HDL-cholesterol ≤50 mg/dl and /or triglycerides 150-400 mg/dl and/or LDL-cholesterol 70 - 150 mg/dl * Lipoprotein (a) \< 30 mg/dl * Patients may have normal glucose metabolism (normal HOMA), be insulin resistant (abnormal HOMA), have impaired fasting glucose or impaired glucose tolerance but not diabetes mellitus. * Without niacin therapy for at least 6 months * Dosage of any concomitant medication has been stable for at least 3 weeks * If female, postmenopausal (absence of menstruation for at least 12 months or absence of menstruation \> 6 months with FSH \> 40 ng/ml respectively oestrogen \< 20 pg/ml) Exclusion Criteria: * Subjects with additional causes for hyperlipoproteinemia * Diabetes mellitus or antidiabetic medication * Subject has history of cardiovascular ischemia in previous 3 months or acute myocardial infarction or unstable angina * History of psychiatric disorder or cognitive impairment that would interfere with participation in the study * History of alcoholism * Contraindication against niacin and/or laropiprant * Subject has participated in an investigational study within 30 days prior to study initiation * Fasting triglycerides \>400 mg/dl * Life-threatening disease (e.g. cancer) * Renal insufficiency (GFR ≤ 30 ml/min ) * Major hepatic impairment * Known allergic reaction/intolerance against niacin and/or laropiprant * Active peptic ulcer disease